share_log

Keybanc Maintains Overweight on Health Catalyst, Lowers Price Target to $10

Keybanc Maintains Overweight on Health Catalyst, Lowers Price Target to $10

Keybanc維持對健康催化劑的增持,將目標股價下調至10美元
Benzinga ·  02/26 05:19

Keybanc analyst Scott Schoenhaus maintains Health Catalyst (NASDAQ:HCAT) with a Overweight and lowers the price target from $12 to $10.

Keybanc分析師斯科特·舍恩豪斯維持Health Catalyst(納斯達克股票代碼:HCAT)增持,並將目標股價從12美元下調至10美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論